Bedrijfsoverzicht
Alpha Cognition Inc. is a biopharmaceutical enterprise primarily engaged in the development of therapeutic treatments for patients suffering from neurodegenerative diseases within the United States and Canada. The company operates within the Healthcare sector, specifically under the Biotechnology industry, which implies a focus on high-risk, high-reward research and development activities aimed at addressing complex medical conditions. As of the latest data, the company possesses a market capitalization of $131.30M and reports annual revenue of $10.22M, while the specific count of employees is not disclosed in available records. These valuation and revenue figures indicate that Alpha Cognition Inc. operates as a mid-cap entity with a relatively narrow revenue base, suggesting that its current financial position is heavily reliant on successful commercialization efforts rather than established, large-scale sales volumes typical of mature pharmaceutical firms.
Financiële gezondheid
The company reported a revenue of $10.22M over the trailing twelve months, yet this figure contrasts sharply with a net income of $-20,669,876 and an EBITDA of $-22,602,116, revealing a cost structure where operating expenses significantly outpace top-line generation. The free cash flow stands at $-14,043,052, which indicates that the company is currently burning cash to fund its R&D and commercialization programs, limiting immediate financial flexibility for dividends or large-scale acquisitions without external capital. Regarding profitability metrics, the gross margin is 81.3%, reflecting efficient production or low cost of goods sold relative to sales, while the operating margin sits at -283.7% and the profit margin at -202.2%, indicating that overhead costs and R&D expenditures are currently exceeding gross revenues by substantial multiples. The balance sheet shows a cash position of $66.05M against zero debt, creating a scenario where the company holds significant liquidity without any leverage obligations. This conservative balance sheet is further supported by a current ratio of 8.65, suggesting an extremely strong ability to meet short-term liabilities with its available liquid assets. Furthermore, the return on equity is -40.7% and the return on assets is -21.7%, metrics that reveal that management is currently generating negative returns on the capital invested, a common characteristic for early-stage biotechnology companies developing novel therapies rather than profitable commercial products.
Waarderingsbeoordeling
The valuation metrics present a complex picture, with a trailing P/E ratio listed as N/A due to the negative earnings, while the forward P/E is calculated at -31.74, reflecting market expectations of future losses or a re-rating required before profitability is achieved. The price-to-book ratio is 2.10, which indicates that the market values the company at more than double its book value, suggesting a premium assigned to the intangible assets and potential of its pipeline despite current unprofitability. Alternative valuation measures such as the price-to-sales ratio of 12.85 and an EV/EBITDA of -2.89 suggest that investors are pricing the stock based on sales growth potential and asset backing rather than current earnings power. In terms of trading range, the 52-week high was $11.54 and the 52-week low was $3.97, placing the current valuation context within a wide band of volatility often seen in speculative biotechnology stocks. The stock exhibits a beta of 2.52, meaning the stock price is expected to be significantly more volatile than the broader market, moving approximately 2.5 times as much as the market index during periods of fluctuation.
Growth & Income
The company's revenue growth year-over-year is listed as N/A, and earnings growth year-over-year is also N/A, preventing a direct comparison of earnings acceleration against revenue expansion in the current reporting period. As the company does not distribute dividends, the dividend yield is N/A and the payout ratio is 0.0%, which confirms that Alpha Cognition Inc. retains all available earnings and cash flow to reinvest into its research and development activities rather than distributing income to shareholders. This strategy of retaining earnings is standard for biotechnology firms in the development phase, where capital expenditure is prioritized to advance clinical trials and secure regulatory approval for products like ZUNVEYL. Consequently, the overall growth and income profile is defined by a lack of current dividend income and undefined growth rates, relying entirely on the successful execution of its commercial development program to transition from cash burn to profitability in the future.